Scientists say study findings indicate that TC IV cells may represent a therapeutic target for the treatment of ...

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows ...

How malaria parasites exploit mechanism for escaping elimination could provide novel strategies targeting chronic malaria ...

Estrogen-related receptors (ERRs) regulate muscle mitochondria in mice, revealing a new potential drug targets for metabolic ...

Researchers were able to test how viruses replicate differently across various bat species and organs using the new organoid ...

CEO Serge Saxonov, PhD, acknowledged that its R&D operation “definitely ended up being impacted in a substantial way” while ...

Imprint has raised $15 million to decode the body's immune memory for understanding chronic diseases, such as long-COVID and ...

Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 ...

In addition to complementing AAV manufacturing, the company’s Plasmid DNA (pDNA) platform is now available as a standalone service.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a ...

Results highlight importance of addressing overwork as an occupational health concern, and the need for workplace policies to ...